{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-22-000058","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.767911+00:00","generated_at":"2026-06-22T02:54:50.675117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme Q3 revenue $209M (+80% YoY); GAAP EPS $0.44, non-GAAP $0.74","bullets":["Royalty revenue $99.6M (+70% YoY) driven by DARZALEX SC and Phesgo.","Reiterates FY 2022 revenue guidance $655-685M; non-GAAP EPS $2.10-2.25.","Completed $720M convertible notes offering; repurchased $200M shares YTD.","Antares Pharma acquisition contributed product sales; operating income $83.3M.","Partner milestones: Roche Tecentriq SC met endpoints, argenx BLA for efgartigimod SC."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-22-000058","json":"https://secwatch.observer/filing/0001159036-22-000058.json","markdown":"https://secwatch.observer/filing/0001159036-22-000058.md","text":"https://secwatch.observer/filing/0001159036-22-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/0001159036-22-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/halo-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:54:50.675117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4c30abf88591d07243c7b7ac805161fdf28a421","claim":"HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue $209 million, EPS $0.44. Guidance reaffirmed.","evidence_excerpt":"Revenue for the third quarter was $209 million compared to $115.8 million for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/0001159036-22-000058-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$209 million"},{"label":"EPS","value":"$0.44"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}